We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

Implantable Hepatic Artery Infusion Pump Delivers Targeted Chemotherapy for Inoperable Tumors

By HospiMedica International staff writers
Posted on 30 Jun 2023
Print article
Image: Intera 3000 is the only FDA-approved pump for HAI therapy (Photo courtesy of Intera Oncology)
Image: Intera 3000 is the only FDA-approved pump for HAI therapy (Photo courtesy of Intera Oncology)

Colorectal cancer ranks fourth in causing cancer-related deaths in the U.S. For up to 25% of patients diagnosed with this disease, the cancer metastasizes to the liver, where it becomes challenging to treat. Now, an innovative chemotherapy delivery system can help colorectal cancer patients with inoperable liver tumors due to metastasis. This breakthrough treatment minimizes toxic exposure and makes surgical interventions feasible for some patients with colon cancer metastasized to the liver.

Intera Oncology’s (Boston, MA, USA) Intera 3000 HAI Pump is the only FDA-approved pump for Hepatic Artery Infusion (HAI) therapy for the treatment of intrahepatic cholangiocarcinoma (bile duct cancer confined to the liver) and colorectal cancer liver metastases. The palm-sized Intera 3000 HAI Pump is implanted in the abdomen and continuously delivers chemotherapy directly to the hepatic artery, which feeds metastatic tumors in the liver. Patients undergoing HAI therapy can maintain their everyday activities with minimal disruption. Remarkably, the Intera 3000 HAI Pump provides up to 400 times the concentration of medication to liver tumors compared to conventional IV administration.

This therapy is ideal for patients with widespread metastatic disease, where curative surgery is not initially feasible. Previously, the best treatment option for these patients was lifelong chemotherapy, which carries potential systemic toxicities and rarely shrinks the tumor size to operable levels. The Intera 3000 HAI Pump offers an alternative, liver-focused treatment that could potentially make patients eligible for surgery by specifically targeting liver disease. Since most of these tumors draw their blood supply from the hepatic arterial system, delivering chemotherapy through this system allows for higher doses of specific chemotherapeutic agents without exposing the patient to their systemic toxicities.

Related Links:
Intera Oncology 

Print article


Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.